<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271997</url>
  </required_header>
  <id_info>
    <org_study_id>Ironsuppletion</org_study_id>
    <nct_id>NCT02271997</nct_id>
  </id_info>
  <brief_title>Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass</brief_title>
  <acronym>Ironsuppletion</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre randomized controlled trial to evaluate the optimal treatment for patients who
      developed an iron deficiency after Roux-en-Y Gastric bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Morbid obesity is worldwide a still growing problem. The number of bariatric procedures are
      still increasing with 9000 bariatric operations in 2009. The golden standard is the Roux-en-Y
      Gastric bypass (RYGB). The RYGB ensures an excess weight loss of 60-70% in our hospital.

      Unfortunately vitamin and mineral deficiencies are a consequence from RYGB. Iron deficiency
      occurs in 14-66% in the first two years after surgery. Worldwide there are three most used
      options of treatment for this: treatment with ferrous fumarate, ferrous gluconate and
      intravenous injection of Ferinject.

      Our goal is to determine which treatment is the most effective to normalize ferritin values
      in the blood and which treatment is the most cost-effective one after a RYGB.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>normal value serum ferritin</measure>
    <time_frame>1 year</time_frame>
    <description>1 year after initiating therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patients preference for oral or intravenous therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Ferrous fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 patients receive ferrous fumarate 3 times a day 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous gluconate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 patients receive ferrous gluconate 2 times a day 695 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron(III)carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 patients receive a single intravenous shot of ferinject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous fumarate</intervention_name>
    <description>treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured</description>
    <arm_group_label>Ferrous fumarate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous gluconate</intervention_name>
    <description>treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured</description>
    <arm_group_label>Ferrous gluconate</arm_group_label>
    <other_name>Losferron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron(III)carboxymaltose</intervention_name>
    <description>treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured</description>
    <arm_group_label>Iron(III)carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all women who underwent a Roux-en-Y gastric bypass and developed an iron deficiency
             postoperatively (ferritin&lt;20microgram/L)

        Exclusion Criteria:

          -  iron deficiency peroperative, blood transfusions during study period, iron containing
             nutritional supplements except the standard multivitamins after bariatric surgery,
             decreased renal failure, excessive blood loss due to menstruation, anemia not caused
             by iron deficiency, accumulation of iron, hypersensitivity for noe of the medicinal
             products, psychiatric illness, pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OLVG West/ Sint Lucas Andreas Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6800WC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferrous fumarate</mesh_term>
    <mesh_term>Ferrous gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

